IGF-1 LR3 2mg — Vial Spec, Reconstitution Math & COA

IGF-1 LR3 2mg Vial Specification & Laboratory Overview

The 2mg vial format of Long R3 Insulin-like Growth Factor-1 (IGF-1 LR3) is specifically designed for high-throughput laboratory research applications requiring sustained experimental dosing or large-batch cell culture media supplementation. Containing 2,000 micrograms of high-purity lyophilized recombinant protein, this vial capacity provides investigators with sufficient mass to execute multi-week longitudinal studies in rodent models or extensive in vitro cell line exposures without the inter-vial variation that can occur when transitioning between smaller mass units.

IGF-1 LR3 is a synthetic, 83-amino-acid analog of human IGF-1. The structural modifications—namely the substitution of Glutamic acid for Arginine at position 3 and a 13-amino-acid extension peptide at the N-terminus—were engineered to dramatically reduce the peptide's affinity for endogenous Insulin-like Growth Factor Binding Proteins (IGFBPs). In laboratory research settings, this altered binding kinetics results in a significantly extended biological half-life compared to native IGF-1, allowing researchers to evaluate continuous Akt/mTOR signaling pathways, protein synthesis rates, and satellite cell proliferation with reduced clearance rates.

When sourcing materials, principal investigators require absolute confidence in sequence identity and net peptide content. While PX1 Research offers standard research configurations available in our IGF-1 LR3 product page, evaluating the 2mg vial specification is critical for protocols demanding precise concentration calculations, minimal solvent volume additions, and standardized aliquot distribution.

Structural Biochemistry and Extended Half-Life Mechanism

In mammalian physiology and isolated cellular models, native IGF-1 interacts dynamic with six distinct binding proteins (IGFBP-1 through IGFBP-6). These carrier proteins sequester free IGF-1, controlling its bioactivity and maintaining circulating reservoirs. In cell culture media containing serum or in vivo blood plasma, native IGF-1 is rapidly bound, limiting its unbound bioactivity to a half-life of less than 30 minutes.

The molecular architecture of Long R3 IGF-1 overcomes this experimental constraint. By incorporating the Arg3 substitution alongside the 13-amino-acid N-terminal extension sequence (MFPAMPLLSLFVN), the steric hindrance and charge alteration fundamentally disrupt the binding surface recognized by IGFBPs. Preclinical binding assays demonstrate that IGF-1 LR3 exhibits over a 1,000-fold reduction in affinity for IGFBPs while fully maintaining functional affinity for the Type 1 IGF Receptor (IGF-1R).

Consequently, free IGF-1 LR3 remains biologically active within culture media or interstitial spaces for extended periods, boasting an estimated half-life exceeding 20 hours in rodent models. This sustained receptor activation triggers robust downstream phosphorylation cascades, principally the Phosphoinositide 3-kinase (PI3K) / Protein Kinase B (Akt) pathway, driving downstream effectors such as p70S6K and 4E-BP1 to accelerate protein synthesis in myocyte assays.

Reconstitution Mathematics for a 2mg IGF-1 LR3 Vial

Accurate reconstitution is vital for maintaining precise concentration control across bioassays. Reconstitution involves dissolving the 2,000 micrograms (2mg) of lyophilized cake into a known volume of sterile diluent—typically 0.6% acetic acid or bacteriostatic water containing 0.9% benzyl alcohol, depending on the desired storage duration and assay sensitivity. To assist laboratory personnel in computing precise dilution ratios, investigators should consult the PX1 reconstitution calculator.

When reconstituting a 2mg (2,000 mcg) vial, final mass concentration depends directly on the volume of diluent added:

• **1.0 mL Diluent Addition:** Yields a final concentration of 2,000 mcg/mL (2.0 mcg/µL). A standard 0.1 mL (10 unit graduation on a U-100 syringe) volume delivers exactly 200 mcg of active peptide.

• **2.0 mL Diluent Addition:** Yields a final concentration of 1,000 mcg/mL (1.0 mcg/µL). A 0.1 mL volume delivers 100 mcg of active peptide, providing an optimal concentration for moderate-dose animal study aliquots.

• **3.0 mL Diluent Addition:** Yields a final concentration of 666.67 mcg/mL (0.667 mcg/µL). A 0.1 mL volume delivers approximately 66.7 mcg of active peptide, which is advantageous when pipetting micro-volumes into low-volume cell culture wells.

Because proteins like IGF-1 LR3 can adhere to glass and plastic walls via hydrophobic interactions, diluent should be introduced gently along the inner glass wall of the vial. Never shake or vortex the vial, as shear forces can induce protein denaturation and aggregation. Gently swirl the solution until complete dissolution is achieved.

Aliquot Planning and Degradation Mitigation

Because a 2mg vial provides a substantial total mass of peptide, repeated freeze-thaw cycles of a single reconstituted solution will inevitably degrade the tertiary structure of the protein, leading to loss of bioactivity and fragment generation. To preserve molecular integrity across long-term experimental schedules, researchers must implement a strict aliquot protocol immediately following initial reconstitution.

Upon full dissolution, the working solution should be immediately divided into single-use microcentrifuge tubes (preferably low-protein-binding polypropylene) calibrated to the exact volume required per assay run. For instance, if an in vitro assay requires 20 mcg of IGF-1 LR3 per media change, a 1,000 mcg/mL stock solution should be aliquoted in 20 µL volumes.

If reconstituting with plain sterile water or saline without an acidic buffer, the solution should be utilized immediately or stored short-term, as neutral pH accelerates peptide aggregation over time. For extended storage of reconstituted IGF-1 LR3, utilizing a reconstitution medium containing 0.1% Bovine Serum Albumin (BSA) or human serum albumin (HSA) acts as a carrier protein, preventing non-specific binding of the peptide to the plastic tube walls.

Storage Benchmarks and Thermal Stability

Lyophilized IGF-1 LR3 demonstrates high stability when maintained under proper environmental controls prior to reconstitution. Unopened 2mg vials should be stored at -20°C to -80°C in a desiccated environment protected from light exposure. Under these deep-freeze conditions, the lyophilized peptide cake remains stable for up to 24 months without measurable loss of mass purity.

For short-term operational handling during transit or temporary lab storage prior to reconstitution, the lyophilized powder can tolerate room temperature conditions (20°C to 25°C) for up to several days without significant degradation. However, immediate refrigeration or freezing upon receipt is recommended to uphold maximum shelf life.

Once reconstituted, thermal tolerance drops significantly. Reconstituted IGF-1 LR3 stored at 2°C to 8°C in an acidic diluent (e.g., 10mM to 100mM acetic acid or 0.6% acetic acid) maintains biological activity for approximately 21 to 30 days. Reconstituted aliquots stored at -80°C are stable for up to 6 months. Repeated freeze-thaw cycles must be rigorously avoided.

Lot-Matched COA Analysis: Mass Spectrometry & HPLC Verification

Quality control in peptide synthesis requires rigorous analytical verification to ensure experimental reproducibility. At PX1 Research, every production lot of lyophilized peptide undergoes comprehensive analytical testing before distribution. Researchers can review and verify these parameters directly through our dedicated Certificate of Analysis repository.

A lot-matched COA for an IGF-1 LR3 2mg vial contains two primary analytical data sets:

1. **High-Performance Liquid Chromatography (HPLC):** Used to determine chromatographic purity. Peak area integration ensures that the target recombinant protein represents ≥98.0% of the total peptide content, verifying the absence of incomplete synthetic fragments or oxidation products.

2. **Mass Spectrometry (MS):** Confirms exact molecular mass identity. For IGF-1 LR3 (theoretical molecular weight approximately 9,111 Da), matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF) or electrospray ionization (ESI-MS) confirms that the synthesized sequence matches the theoretical mass within tight tolerance limits.

Additionally, because cell culture models and in vivo preclinical protocols are highly sensitive to pyrogenic contamination, PX1 Research subjects lots to Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.01 EU/µg. Every batch is manufactured in GMP-compliant facilities and tested in ISO 17025 accredited analytical laboratories.

Comparative Benchmarking: IGF-1 LR3 vs. IGF-1 DES & Growth Hormone Secretagogues

When designing protocols to investigate growth factor pathways, researchers often evaluate several related compounds within the growth hormone / IGF axis to select the optimal ligand for their specific receptor kinetic targets.

In contrast to IGF-1 LR3, IGF-1 DES is a truncated variant lacking the first three amino acids (Gly-Pro-Glu) at the N-terminus. This truncation reduces IGFBP affinity while drastically shortening its biological half-life to minutes, making IGF-1 DES ideal for hyper-localized target tissue studies requiring localized activity without systemic receptor saturations. Meanwhile, research into upstream somatotropic pathway activation frequently incorporates growth hormone secretagogues such as CJC-1295 No DAC or peptides targeting the growth factor cascade like MGF. While secretagogues induce endogenous pituitary GH release—which subsequently stimulates hepatic native IGF-1 production—direct administration of recombinant IGF-1 LR3 bypasses the neuroendocrine axis entirely, offering direct receptor occupancy control in vitro and in vivo.

For a broader overview of comparative pathways and experimental setups across various peptide classes, scientists can explore our centralized research documentation library.

In Vitro Assay Protocols and Preclinical Cell Models

In cellular biology laboratories, IGF-1 LR3 is widely utilized to probe signaling networks governing cell proliferation, differentiation, and survival. Primary skeletal muscle myoblasts (such as C2C12 cell lines) represent one of the most common research models for this compound.

Preclinical in vitro studies demonstrate that exposing myoblasts to nanomolar concentrations (e.g., 10 ng/mL to 100 ng/mL) of IGF-1 LR3 accelerates the expression of myogenic regulatory factors, including MyoD and Myogenin. This accelerates myoblast fusion into multinucleated myotubes. Furthermore, in vitro assays show that IGF-1 LR3 potently inhibits autophagic degradation pathways and ubiquitin-proteasome systems (specifically suppressing MuRF1 and MAFbx/Atrogin-1 expression), shifting net cellular protein balance toward accretion.

In primary neuronal and cardiac cell cultures, preclinical data indicate that IGF-1 LR3 activation of the ERK1/2 and Akt pathways confers neuroprotective and cardioprotective effects against oxidative-stress-induced apoptosis, providing a rich framework for metabolic and regenerative tissue research.

Selecting the Optimal Vial Size: 1mg vs. 2mg Laboratory Configurations

Selecting the correct vial size depends directly on experimental scale, subject number, and reconstitute shelf-life considerations. The 2mg vial mass format is optimal for high-volume research applications, such as daily administration across large rodent cohorts or multi-plate cell culture experiments where high working stock volumes are consumed within 2 to 3 weeks.

However, for small-scale pilot studies, infrequent assay runs, or projects requiring minimal reconstituted storage times, a smaller 1mg vial unit may prevent waste and eliminate concerns regarding long-term aqueous stability. Ordering smaller unit sizes allows research groups to reconstitute fresh working solutions strictly as needed.

When planning procurement, research facilities can evaluate bulk requirements or register for specialized laboratory terms through the PX1 wholesale account portal. Regardless of the specific mass configuration selected, PX1 Research ships all orders directly from our USA distribution hubs in California and Arizona with same-day shipping on orders placed Monday through Friday.